Navigation Links
Particle Sciences and Eyeon Therapeutics Receive Patent on Novel Dry Eye Technology
Date:7/22/2014

BETHLEHEM, Pa., July 22, 2014 /PRNewswire/ -- Eyeon Therapeutics has received a Notice of Allowance on a novel dry eye treatment based on a charged hydrophilic polymer developed at Particles Sciences, a leading drug delivery CDMO.  The product has been shown to be safe and effective in a small trial previously published.  Mark Mitchnick, MD, CEO states, "This first set of claims around the polymer and its class will go a long way to moving this technology into the commercial phase.  We have been using it in several development projects, and we believe it has promise in many ocular formulations as well as in other areas.  Helping Eyeon gain a proprietary position in this very important market is a great example of what Particle Sciences offers its partners." 

David Kleinman, MD, CEO of Eyeon Therapeutics commented, "Dry eye is a serious and growing problem for which there are few therapies.  Our product offers a unique approach that is clinically validated and useful in a number of ocular applications.  In the coming months we will be pursuing partnerships and expanded protection around this product and follow-ons." 

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Particle Sciences is FDA registered and DEA licensed. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com, email info@particlesciences.com, or contact us at (610) 861- 4701 for information.

Eyeon Therapeutics, Inc. is a privately held ophthalmic products development company focused on advancing early-stage technologies from white board to clinical proof of concept. The company was founded in 2004 and is headquartered in Rochester, New York. Contact David Kleinman at dave@eyeontherapeutics.com

Contact:
Maureen Grieco
610-861-4701
Maureen.grieco@particlesciences.com


'/>"/>
SOURCE Particle Sciences
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Particle Measuring Systems® Celebrates 40 Years of Leadership
2. Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films
3. Aethlon Medical Announces Notice of Allowance of U.S. Patent Application Covering a Medical Device to Remove Microvesicular Particles, Including Exosomes
4. Sigma-Aldrich Accelerates Analytical Research and Extends Benefits of Fused-Core Particle Technology to All HPLC Users with the Launch of New Ascentis Express 5 Micron Particle by Supelco
5. Varian Medical Systems Signs Purchase Agreement with Advanced Particle Therapy LLC to Supply Technology for the Georgia Proton Treatment Center to be operated by Emory Healthcare
6. Particle Sciences Develops Novel Ocular Formulation for Eyeon Therapeutics
7. Particle Sciences and NETZSCH Premier Technologies Enter into Collaboration
8. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
9. Waters Introduces CORTECS Columns Featuring Solid-Core Particle Technology
10. HORIBA Scientific Launches New Raman ParticleFinder Software
11. The Japanese Embolization Particle Market Will Witness Significant Market Activity And Rapid Growth Due To New Product Approvals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
(Date:8/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the ... in New York . John Greisch ... present at 11:05 a.m. Eastern Time. The ... A recorded replay will be available one hour after the ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... ... 19, 2017 , ... The American College of Lifestyle ... recently formed Corporate Roundtable, a group of individuals and organizations whose collective vision ... Canyon Ranch is a unique collection of lifestyle-based immersion vacation settings and programs ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... issued a rallying cry to Americans to watch for the discomforts and hidden ... young athletes to senior citizens, everyone is at risk for developing fungal infections ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets ... (published by Xlibris on July of 2014). This book details the recent advances and ... approaches that benefit people who have lost all of their natural teeth . ...
(Date:9/19/2017)... Va (PRWEB) , ... September 19, 2017 , ... The ... the use of health IT to create efficiencies in healthcare information exchange and a ... the release of their latest industry white paper, entitled Barriers to Adoption of ...
Breaking Medicine News(10 mins):